摘要:
The present invention addresses a novel condensed heterocyclic compound which has a sepiapterin reductase inhibitory action and is particularly useful for treatment of a pain. Provided are a novel condensed heterocyclic compound represented by Formula (I) below (although each substituent is defined in the description, R 1 represents a hydrocarbon group or the like; R 2 and R 3 represent a hydrogen atom or the like; R 4 represents a substituent defined in the description; X represents a substituent defined in the description; and Y represents a substituent defined in the description), a tautomer or a pharmaceutically acceptable salt of the compound, or a solvate of any of these.
摘要:
This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.
摘要:
This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.
摘要:
The present invention is the following Amphotericin B derivative:
wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.
摘要:
A process for the preparation of a compound of formula (I):
wherein R 1 is each independently halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy or C1-C6 alkylcarbonyl, R 3 is C1-C6 alkyl; C3-C8 cycloalkyl; or phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl; C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy, n is an integer of 0 to 2, X is S atom or O atom,
its salt or solvate thereof characterized by reacting a compound of formula (IV):
wherein R 1 , n and X have the same meaning as defined above, and R 2 is C1-C6 alkyl; C1-C6 haloalkyl; or phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy and nitro,
with a compound of formula (V):
wherein R 3 has the same meaning as defined above.
摘要:
The present invention is related to a compound represented by formula (I)
wherein R 1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is -N(R 3 )-, -O-, or -S-; Y is =C(R 4 )-, or =N-; Z is -N(R 7 )-, -O-, or -S-; R 2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: -(CR 2a R 2b ) n -R 2c , wherein R 2a is each independently a hydrogen atom, halogen, or the like; R 2b is each independently a hydrogen atom, halogen, or the like; R 2a and R 2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R 2a which are attached to the adjacent carbon atoms and/or two of R 2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R 2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R 3 and R 7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R 4 and R 5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R 6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.
摘要:
The present invention discloses novel piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), a pharmaceutically acceptable salt or a solvate thereof:
wherein A is substituted or unsubstituted monocyclic aryl or monocyclic heterocyclyl; X is a single bond or C(=O); Y is a single bond, CR 5 R 6 NR 7 or C (=O) NR 7 ; R 1 and R 2 are independently hydrogen or substituted or unsubstituted alkyl; R 3 is substituted or unsubstituted aryl or heterocyclyl; R 4 is halogen, substituted or unsubstituted alkyl, alkoxy, aryloxy or heterocyclyloxy, etc.; p is an integer of 0 to 2; q is 0 or 1; m is 0 or 1; n is an integer of 0 to 5; and B is aromatic carbocycle, monocyclic heterocycle or bicyclic fused hetero ring.
摘要翻译:本发明公开了具有NPY Y5受体拮抗活性的新型哌啶和吡咯烷衍生物。 具体地说,本发明公开了由式(I)表示的化合物,其药学上可接受的盐或溶剂合物:其中A是取代或未取代的单环芳基或单环杂环基; X是单键或C(= O); Y是单键,CR 5 R 6 NR 7或C(= O)NR 7; R 1和R 2独立地为氢或取代或未取代的烷基; R 3是取代或未取代的芳基或杂环基; R 4是卤素,取代或未取代的烷基,烷氧基,芳氧基或杂环氧基等; p为0〜2的整数。 q为0或1; m为0或1; n为0〜5的整数, 和B是芳族碳环,单环杂环或双环稠合杂环。
摘要:
The present invention discloses novel cyclohexane derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), or a pharmaceutically acceptable salt or a solvate thereof:
wherein A is substituted or unsubstituted aryl or heterocyclyl; a combination of X and Y is a combination selected from (X, Y)=(C(=O)N(R 1 ), C(=O)N(R 2 )), (C(=O)N(R 1 ), imidazole-1,3-diyl), (N(R 1 ), C(=O)N(R 2 )), (O, C(=O)N(R 2 )), (C(R 3 )(R 4 ), N(R 2 )) or (a single bond, C(=O)N(R 2 )); R 1 , R 2 and R 3 are independently hydrogen or substituted or unsubstituted alkyl; R 5 is substituted or unsubstituted aryl or heterocyclyl; R 6 is halogen, oxo, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy; m is 0 or 1; and n is an integer of 0 to 5; and B is aromatic carbocycle, monocyclic heterocycle or fused bicyclic heterocycle.